Xconomy Boston

PerkinElmer-ViaCell Deal Clears Antitrust Hurdle

Rebecca Zacks10/25/07

Yesterday marked the expiration of the antitrust waiting period for Waltham, MA-based PerkinElmer’s (NYSE: PKI) planned acquisition of Cambridge’s ViaCell (NASDAQ: VIAC). The $300 million deal, announced about three weeks ago, boosted ViaCell’s shares more than 50 percent, and should close later this quarter.

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.